Table 1.
Summary of recommendations for anti-COVID therapies in cancer patients.
| Therapy | Setting | Recommendation | Evidence |
|---|---|---|---|
| Nirmatrelvir/Ritonavir (Paxlovid) | Nonhospitalized, mild to moderate disease | IN FAVOR, start within 5 days of symptoms onset | A |
| Remdesivir | Nonhospitalized and hospitalized, mild to severe disease | IN FAVOR, start within 7 days of symptoms onset | B |
| Monoclonal antibodies | Nonhospitalized, mild to moderate disease | AGAINST | B |
| Dexamethasone | Nonhospitalized | AGAINST | A |
| Hospitalized, requiring oxygen | IN FAVOR | B | |
| Baricitinib | Hospitalized, requiring high-flow oxygen | IN FAVOR, preferred option | B |
| Tocilizumab | Hospitalized, requiring high-flow oxygen | IN FAVOR, preferred alternative | B |
| Abatacept | Hospitalized, requiring high-flow oxygen | IN FAVOR, additional alternatives | C |
| Infliximab | Hospitalized, requiring high-flow oxygen | IN FAVOR, additional alternatives | C |
| Fluvoxamine | Nonhospitalized, mild to moderate disease | AGAINST | A |
| Intravenous immunoglobulins | Nonhospitalized, mild to moderate disease | AGAINST | A |
| Ivermectin | Nonhospitalized, mild to moderate disease | AGAINST | A |
| Metformin | Nonhospitalized, mild to moderate disease | AGAINST | B |